Company profile

CombiGene company profile

CombiGene provides patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. CombiGene is developing a breakthrough therapy with the potential to dramatically improve the quality of life for a group of epilepsy patients for whom there is currently no effective treatment. CombiGene uses an adeno-associated viral vector (AAV) to administer a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the part of the brain where the epileptic seizure begins. The..... For more information, log in to dureach.com to view the full company profile.

Business identity

Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$0+
Founded
2008-01-01

Headquarters

Headquarters
Lund, Skane Lan, Sweden
Postal code
223 81
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Ipo
Funding rounds
2
Last funding
Post Ipo Equity / 2024-02-21
Last equity funding
Post Ipo Equity
Investors
2
Lead investors
2
Founders
2
Articles
44
Exited on
2015-05-25

Founders and investors

Founders

David WoldbyeMerab Kokaia

Lead investors

Horizon 2020Orphazyme

Investors

Horizon 2020Orphazyme

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.